医院获得性与社区获得性碳青霉烯耐药肠杆菌目感染死亡率比较:医院获得性更高
研究基于CRACKLE-2前瞻性队列,纳入10国56家医院891例碳青霉烯耐药肠杆菌目血流感染患者,按CDC标准分为医院获得性与社区获得性。医院获得性占65%(582/891),30天死亡率33%(192/582)高于社区获得性21%(66/309),P<0.001;随机选取的社区获得性患者获得更优DOOR结局的概率为60.6%(95%CI 56.8%-64.3%)。
要点
- 医院获得性碳青霉烯耐药肠杆菌目血流感染占65%(582/891)。
- 医院获得性30天死亡率33%(192/582)高于社区获得性21%(66/309),P<0.001。
- 社区获得性患者获得更优DOOR结局概率60.6%(95%CI 56.8%-64.3%)。
核心结论
- 医院获得性碳青霉烯耐药肠杆菌目血流感染较社区获得性对患者结局影响更大,CDC报告医院获得性感染增加需严格监测和感染防控以减少额外死亡。
研究设计与样本
- 前瞻性队列研究,纳入CRACKLE-2中2016年4月30日至2019年11月30日10国56家医院891例碳青霉烯耐药肠杆菌目血流感染患者,按CDC指南定义医院获得性或社区获得性并比较特征与结局。
主要发现
- 891例中医院获得性占65%(582/891)。
- 医院获得性患者较社区获得性更年轻[中位60岁(Q1 42,Q3 70) vs 65岁(52,74),P<0.001],合并症更少[Charlson合并症指数中位2(1,4) vs 3(1,5),P=0.002]。
- 医院获得性患者病情更重(Pitt菌血症评分≥4:47% vs 32%,P<0.001)。
- 随机选取的社区获得性患者较医院获得性患者获得更优DOOR结局的概率为60.6%(95%CI 56.8%-64.3%)。
- 医院获得性30天死亡率33%(192/582)高于社区获得性21%(66/309),P<0.001。
关键数值与推荐
- 感染按CDC指南定义为社区获得性或医院获得性。
- 主要结局为索引培养后30天的DOOR。
- 30天死亡率差异以95%CI计算。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The CDC reported a 35% increase in hospital-onset (HO) carbapenem-resistant Enterobacterales (CRE) infections during the COVID-19 pandemic. We evaluated patient outcomes following HO and community-onset (CO) CRE bloodstream infections (BSI). METHODS: Patients prospectively enrolled in CRACKLE-2 from 56 hospitals in 10 countries between 30 April 2016 and 30 November 2019 with a CRE BSI were eligible. Infections were defined as CO or HO by CDC guidelines, and clinical characteristics and outcomes were compared. The primary outcome was desirability of outcome ranking (DOOR) 30 days after index culture. Difference in 30-day mortality was calculated with 95% CI. RESULTS: Among 891 patients with CRE BSI, 65% were HO (582/891). Compared to those with CO CRE, patients with HO CRE were younger [median 60 (Q1 42, Q3 70) years versus 65 (52, 74); P < 0.001], had fewer comorbidities [median Charlson comorbidity index 2 (1, 4) versus 3 (1, 5); P = 0.002] and were more acutely ill (Pitt bacteraemia score ≥4: 47% versus 32%; P < 0.001). The probability of a better DOOR outcome in a randomly selected patient with CO BSI compared to a patient with HO BSI was 60.6% (95% CI: 56.8%-64.3%). Mortality at 30-days was 12% higher in HO BSI (192/582; 33%) than CO BSI [66/309 (21%); P < 0.001]. CONCLUSION: We found a disproportionately greater impact on patient outcomes with HO compared to CO CRE BSIs; thus, the recently reported increases in HO CRE infections by CDC requires rigorous surveillance and infection prevention methods to prevent added mortality.
引用
- Boutzoukas AE, Mackow N, Giri A, et al. Increased mortality in hospital- compared to community-onset carbapenem-resistant enterobacterales infections. J Antimicrob Chemother. 2024. PMID: 39236214. doi:10.1093/jac/dkae306
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。